TriSalus Life Sciences (NASDAQ:TLSI) Trading Up 2% – Time to Buy?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) shares were up 2% on Wednesday . The company traded as high as $4.50 and last traded at $4.49. Approximately 163,177 shares changed hands during mid-day trading, a decline of 8% from the average daily volume of 177,035 shares. The stock had previously closed at $4.40.

Wall Street Analysts Forecast Growth

TLSI has been the subject of a number of analyst reports. Canaccord Genuity Group lowered their target price on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of TriSalus Life Sciences in a report on Friday, April 10th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.00.

TriSalus Life Sciences Stock Performance

The business has a 50-day moving average of $4.44 and a 200-day moving average of $5.20. The stock has a market capitalization of $285.09 million, a price-to-earnings ratio of -2.54 and a beta of 0.54.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.01. The firm had revenue of $13.21 million for the quarter, compared to analyst estimates of $13.20 million. On average, research analysts predict that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Mary T. Szela sold 15,944 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.85, for a total transaction of $61,384.40. Following the completion of the sale, the chief executive officer owned 752,987 shares in the company, valued at $2,898,999.95. This represents a 2.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 30,150 shares of company stock valued at $119,849. 16.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TLSI. Barclays PLC grew its holdings in shares of TriSalus Life Sciences by 80.2% during the fourth quarter. Barclays PLC now owns 47,699 shares of the company’s stock worth $333,000 after buying an additional 21,231 shares during the last quarter. Nuveen LLC raised its stake in TriSalus Life Sciences by 77.5% during the 4th quarter. Nuveen LLC now owns 36,550 shares of the company’s stock valued at $255,000 after acquiring an additional 15,956 shares during the last quarter. Millennium Management LLC lifted its position in TriSalus Life Sciences by 17.7% during the 3rd quarter. Millennium Management LLC now owns 35,612 shares of the company’s stock worth $166,000 after acquiring an additional 5,359 shares during the period. Deutsche Bank AG acquired a new stake in TriSalus Life Sciences during the 4th quarter worth approximately $164,000. Finally, MetLife Investment Management LLC purchased a new position in shares of TriSalus Life Sciences in the 4th quarter valued at approximately $127,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.